These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 2402227

  • 1. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
    Komuro Y, Imanishi N, Uchida M, Morooka S.
    Mol Pharmacol; 1990 Sep; 38(3):378-84. PubMed ID: 2402227
    [Abstract] [Full Text] [Related]

  • 2. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N, Murakami-Uchida M, Koike H, Natsume Y, Morooka S.
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [Abstract] [Full Text] [Related]

  • 3. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [Abstract] [Full Text] [Related]

  • 4. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM, Fraisse L, Bachy A, Valette G, Savi P, Laplace MC, Lassalle J, Roche B, Lale A, Keane PE.
    J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
    [Abstract] [Full Text] [Related]

  • 5. Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412.
    Handley DA, Van Valen RG, Melden MK, Houlihan WJ, Saunders RN.
    J Pharmacol Exp Ther; 1988 Nov; 247(2):617-23. PubMed ID: 3183958
    [Abstract] [Full Text] [Related]

  • 6. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM, Bernat A, Valette G, Gigo V, Lale A, LaPlace MC, Lespy L, Savi P, Maffrand JP, Le Fur G.
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor.
    Yamada T, Tomioka K, Saito M, Horie M, Mase T, Hara H, Nagaoka H.
    Arch Int Pharmacodyn Ther; 1990 Oct; 308():123-36. PubMed ID: 2099131
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
    Tsunoda H, Sakuma Y, Harada K, Muramoto K, Katayama S, Horie T, Shimomura N, Clark R, Miyazawa S, Okano K.
    Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
    Yamada T, Saito M, Mase T, Hara H, Nagaoka H, Murase K, Tomioka K.
    Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
    [Abstract] [Full Text] [Related]

  • 10. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
    Terashita Z, Imura Y, Takatani M, Tsushima S, Nishikawa K.
    J Pharmacol Exp Ther; 1987 Jul; 242(1):263-8. PubMed ID: 3612533
    [Abstract] [Full Text] [Related]

  • 11. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
    Heuer HO, Casals-Stenzel J, Muacevic G, Weber KH.
    J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
    [Abstract] [Full Text] [Related]

  • 12. Effect of the platelet activating factor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride on endotoxin-induced hypotension and hematological parameters in rats.
    Natsume Y, Imanishi N, Koike H, Morooka S.
    Arzneimittelforschung; 1994 Nov; 44(11):1208-13. PubMed ID: 7848333
    [Abstract] [Full Text] [Related]

  • 13. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Alberts AW, Bugianesi RL, Chabala JC, Ponpipom MM.
    J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
    [Abstract] [Full Text] [Related]

  • 14. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
    Herbert JM, Laplace MC, Maffrand JP.
    J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264
    [Abstract] [Full Text] [Related]

  • 15. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
    Terashita Z, Kawamura M, Takatani M, Tsushima S, Imura Y, Nishikawa K.
    J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
    [Abstract] [Full Text] [Related]

  • 16. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
    Nagaoka J, Harada K, Kimura A, Kobayashi S, Murakami M, Yoshimura T, Yamada K, Asano O, Katayama K, Yamatsu I.
    Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
    [Abstract] [Full Text] [Related]

  • 17. Tea polyphenols inhibit acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine acetyltransferase (a key enzyme in platelet-activating factor biosynthesis) and platelet-activating factor-induced platelet aggregation.
    Sugatani J, Fukazawa N, Ujihara K, Yoshinari K, Abe I, Noguchi H, Miwa M.
    Int Arch Allergy Immunol; 2004 May; 134(1):17-28. PubMed ID: 15051936
    [Abstract] [Full Text] [Related]

  • 18. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. I. Studies on blood platelets in vitro.
    Ostermann G, Hofmann B, Kertscher HP, Till U.
    J Lipid Mediat; 1990 May; 2(1):21-31. PubMed ID: 1966804
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
    Ring PC, Seldon PM, Barnes PJ, Giembycz MA.
    Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
    [Abstract] [Full Text] [Related]

  • 20. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
    Suzuki M, Sugatani J, Ino M, Shimura M, Akiyama M, Yamazaki R, Suzuki Y, Miwa M.
    Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.